Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Miranda Gogishvili"'
Autor:
Mustafa Ozguroglu, Saadettin Kilickap, Igor Bondarenko, Ahmet Sezer, Mahmut Gümüş, Miranda Gogishvili, Xuanyao He, Giuseppe Gullo, Petra Rietschel, Ruben GW Quek
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d567674c409344d1a377a09a1890d0a4
Autor:
Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, Ana Baramidze, Davit Giorgadze, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Siyu Li, Yuntong Li, Manika Kaul, Ruben G.W. Quek, Jean-Francois Pouliot, Frank Seebach, Israel Lowy, Giuseppe Gullo, Petra Rietschel
Publikováno v:
Journal of Thoracic Oncology. 18:755-768
Autor:
Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze, Davit Giorgadze, Mikhail Dvorkin, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Christian Gessner, Brizio Moreno-Jaime, Rodolfo Passalacqua, Siyu Li, Kristina McGuire, Manika Kaul, Anne Paccaly, Ruben G. W. Quek, Bo Gao, Frank Seebach, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Giuseppe Gullo, Petra Rietschel
Publikováno v:
Nature Medicine. 28:2374-2380
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with advanced non-small cell lung cancer
Autor:
Tamta Makharadze, Ruben G. W. Quek, Tamar Melkadze, Miranda Gogishvili, Cristina Ivanescu, Davit Giorgadze, Mikhail Dvorkin, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Christian Gessner, Brizio Moreno‐Jaime, Rodolfo Passalacqua, Gerasimos Konidaris, Petra Rietschel, Giuseppe Gullo
Publikováno v:
Cancer.
Autor:
Mustafa Özgüroğlu, Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş, Igor Bondarenko, Miranda Gogishvili, Xuanyao He, Jennifer McGinniss, Giuseppe Gullo, Petra Rietschel, Ruben GW Quek
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:CLO22-074
Autor:
Mahmut Gümüş, Ahmet Sezer, Eric Yan, Saadettin Kilickap, Igor Bondarenko, Mustafa Özgüroğlu, Miranda Gogishvili, Giuseppe Gullo, Petra Rietschel, Ruben GW Quek
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:CLO22-050
Autor:
Saadettin Kilickap, Ahmet Sezer, Mahmut Gümü&scedil, Igor Bondarenko, Mustafa Ozguroglu, Miranda Gogishvili, Xuanyao He, Giuseppe Gullo, Petra Rietschel, Ruben Quek
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Frank Seebach, Naiyer A. Rizvi, Semra Paydas, Chieh I. Chen, Ahmet Sezer, Mustafa Ozguroglu, Oleg Gladkov, George D. Yancopoulos, Irfan Cicin, David M. Weinreich, Israel Lowy, Mahmut Gumus, Virote Sriuranpong, P. Rietschel, Kristina McGuire, Dmitry Bentsion, Marina Nechaeva, Saadettin Kilickap, Miranda Gogishvili, Bo Gao, Siyu Li, Igor Bondarenko, S. Lee, Giuseppe Gullo, Haci Mehmet Turk, Philip Clingan, Tamta Makharadze
Publikováno v:
The Lancet. 397:592-604
We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%.In EMPOWER-Lung 1, a multicentre, open-label, global,
Autor:
Mahmut Gümüş, Chieh‐I Chen, Cristina Ivanescu, Saadettin Kilickap, Igor Bondarenko, Mustafa Özgüroğlu, Miranda Gogishvili, Haci M. Turk, Irfan Cicin, James Harnett, Vera Mastey, Ulrike Naumann, Matthew Reaney, Gerasimos Konidaris, Medha Sasane, Keri J. S. Brady, Siyu Li, Giuseppe Gullo, Petra Rietschel, Ahmet Sezer
Publikováno v:
CancerREFERENCES. 129(1)
Background In the EMPOWER-Lung 1 trial (, NCT03088540), cemiplimab conferred longer survival than platinum-doublet chemotherapy for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%. Patient-reported outco
Autor:
Christophe Le Tourneau, Caroline Hoffmann, Zoltan Takacsi-Nagy, Xavier Liem, Sébastien Salas, Anais Debard, Laetitia Finzi, Leonard A Farber, Miranda Gogishvili, Giorgi Kristesashvili, Tamta Makharadze, Sue S. Yom
Publikováno v:
Journal of Clinical Oncology. 40:TPS6110-TPS6110
TPS6110 Background: Elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) are largely underrepresented in clinical trials (CT). Broad access to CTs in this population is challenging due to an increased prevalence of